TradingKey

• Charles River expects revenue and earnings reaching the top end of guidance. • Analysts raised price targets following the company's strategic Investor Day presentation. • Global biopharma funding recovery reinforces order flow and booking visibility.

• JPMorgan included Thermo Fisher in its top monthly growth stock selections. • The company reported $44.56B in annual revenue and $6.70B in profit. • Analysts issued Buy ratings with an average price target of $657.95.

• Futu Holdings experienced intraday volatility driven by digital asset initiatives and strategic partnerships. • Annual revenue reached $2.77 billion with net profit totaling $1.45 billion. • Analysts issued Buy ratings with an average price target of $169.83.

• XP shares surged following positive political and macroeconomic developments in Brazil. • Solid operational fundamentals and compressed valuations further supported the stock rally. • Technical indicators show buy signals alongside overbought market conditions.

• Tempus AI shares surged on Wall Street upgrades and new regulatory product clearance. • The company secured extended data licensing partnerships and advanced RNA sequencing foundation models. • Annual revenue reached $1.27 billion alongside a net loss of $245.03 million.

• Illumina surged due to significant price target increases from Wall Street firms. • Strong NovaSeq X placement velocity drove durable fundamental momentum and margin improvements. • Technical indicators show a MACD buy signal and an overbought Williams %R.

• C.H. Robinson agreed to acquire RXO Inc. in a cash-and-stock transaction. • The deal triggered investor sell-offs due to equity dilution and increased leverage. • Management suspended share repurchases to prioritize debt reduction amid soft freight demand.

• Telefônica Brasil surged due to technical momentum and institutional interest. • The company generates steady cash flows from fiber and mobile subscriptions. • The stock's RSI indicates a buy condition at 70.177.

• Favorable analyst revisions and biopharmaceutical funding rebounds drove Danaher's upward stock movement. • Julie Sawyer Montgomery assumed the CEO role following a structured succession plan. • Danaher reports annual revenue of $24.57B and net profit of $3.61B.

• Genmab reported positive clinical trial results for rinatabart sesutecan and epcoritamab. • Wall Street analysts increased price targets following the strong pipeline progress. • Institutional investments and favorable technical indicators drove substantial stock momentum.

• Banco Bradesco surged due to market-friendly political developments in Brazil's presidential election. • Technical indicators show a buy signal with an RSI of 76.665. • The company reported $25.31B in annual revenue and $4.66B in net profit.

• Schneider Electric agreed to acquire PTC Inc. for approximately $22.6 billion in cash. • The transaction unites PTC industrial software with Schneider Electric hardware and automation architecture. • PTC shares will trade near the offer price pending regulatory and shareholder approvals.

• Abbott secured FDA approval for its CardioMEMS heart failure system features. • The company reported annual revenue of $44.33B with net profit of $6.52B. • Analysts issued Buy ratings with an average price target of $121.29.

• Nucor raised product prices across its portfolio amid tight domestic supply conditions. • Trade protections and import tariffs supported domestic market share gains for operators. • Nucor reported annual revenue of $32.49 billion with net profit of $1.74 billion.

• Sabesp shares surged due to investor confidence in post-privatization capital plans. • Technical indicators show a buy signal with an RSI at 79.536. • Sabesp reported annual revenue of $6.81B and net profit of $1.51B.

• Brazil election results and fiscal conservatism boosted Banco Santander Brasil's market sentiment. • Parent buy-in offers and loan book stabilization reinforced institutional investor confidence. • BSBR generated $13.47B annual revenue with analysts maintaining an average hold rating.

• Expanding global refining crack spreads and tight supply fundamentals bolstered Marathon Petroleum shares. • Management's capital allocation strategy prioritizes substantial share repurchases and steady midstream distributions. • Technical indicators show a MACD buy signal alongside an overbought RSI condition.

• OpenAI partnership reassurance and analyst upgrades drove Cerebras Systems' strong stock rebound. • Demand exceeds production capacity, backed by strong revenue and multi-year cloud agreements. • Technical indicators show mixed signals with a MACD sell and neutral RSI.

• Valero Energy rallied due to tight global supply and strong refining crack spreads. • Analysts increased third-quarter earnings estimates amid robust throughput volumes and favorable feedstock pricing. • Technical indicators show a MACD buy signal and an RSI buy condition.

• Moderna joins the Nasdaq-100 Index, driving institutional portfolio rebalancing and share accumulation. • Optimism for the Merck partnershiped oncology pipeline boosts long-term investor market sentiment. • The company reported an annual revenue of $1.94B and net profit of $-2.82B.